18 April 2023
NeoPhore Limited, a small molecule neoantigen immuno-oncology
company, today announces that it has signed a strategic collaboration agreement with Professor Chris
Lord’s lab at The Institute of Cancer Research, London. The collaboration will use NeoPhore’s
proprietary small molecule inhibitors of DNA mismatch repair (‘MMR’) to investigate single agent
activity against tumours with defined genetic backgrounds.